Mara Goldstein
Stock Analyst at Mizuho
(2.87)
# 1,768
Out of 4,984 analysts
77
Total ratings
44.83%
Success rate
9.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $8.09 | +270.83% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.22 | +350.45% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $9.44 | -15.25% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $12.03 | +249.13% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $9.25 | +440.54% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $14.75 | +205.08% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $84.80 | -9.20% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.67 | +319.16% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $0.95 | +742.11% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.31 | +3,735.09% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $51.07 | +76.23% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $5.79 | -39.55% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.00 | +17,900.00% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $8.07 | +147.83% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $81.14 | +60.22% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.93 | +3.63% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.27 | +844.88% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.08 | +11,038.61% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $47.56 | -57.95% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.82 | +513.81% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.46 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $6.19 | +126.17% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $8.09
Upside: +270.83%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.22
Upside: +350.45%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $9.44
Upside: -15.25%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $12.03
Upside: +249.13%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $9.25
Upside: +440.54%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $14.75
Upside: +205.08%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $84.80
Upside: -9.20%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.67
Upside: +319.16%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $0.95
Upside: +742.11%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.31
Upside: +3,735.09%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $51.07
Upside: +76.23%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $5.79
Upside: -39.55%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.00
Upside: +17,900.00%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $8.07
Upside: +147.83%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $81.14
Upside: +60.22%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.93
Upside: +3.63%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.27
Upside: +844.88%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.08
Upside: +11,038.61%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $47.56
Upside: -57.95%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.82
Upside: +513.81%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $24.46
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $6.19
Upside: +126.17%